BIO-Europe EBD Group BIO BIO-Europe

Thank you for participating in BIO-Europe® 2014

Download your messages and statistics, bookmark and set notifications to track your leads, all on partnering360®.

The majority of BIO-Europe® 2014 delegates are already members of partnering360®.

partnering360: maximize your productivity by engaging and finding partners 24/7. Synchronize your in-person partnering with your online activity — all in one place.

See videos of BIO-Europe ►

Save the date and check back in the coming weeks for information on next year's BIO-Europe, November 2–4, 2015 in Munich, Germany.

more ►

Conference videos

A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014
A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2014 November 4, 2014 | BIO-Europe® 2014What makes a "transformative deal"? This panel of pharma CEOs discusses key partnerships from 2014. View session here View session here
Corporate views on personalized immune intervention
Corporate views on personalized immune intervention November 3, 2014 | BIO-Europe® 2014We focus on current developments in personalized immune intervention markets, potential risks, and business strategies to realize the full market potential. View session here View session here
Early market access Early market accessNovember 3, 2014 | BIO-Europe® 2014This session covers the regulatory environment of adapted licensing and the regulatory and reimbursement regime of existing pre-market access in key pharma markets in the EU. View session here View session here
Access to funding for European companies Access to funding for European companiesNovember 3, 2014 | BIO-Europe® 2014A dynamic biotech sector depends on a vital stock market as a source of fresh money. As more EU companies move to the US, what does this mean for EU companies looking for capital? View session here View session here
Mind the GAP? Meeting an emerging demand for access to medicines in late-stage clinical trials, prior to commercial launch
Mind the GAP? Meeting an emerging demand for access to medicines in late-stage clinical trials, prior to commercial launch November 3, 2014 | BIO-Europe® 2014This panel discusses the roles that pharma, biotech, regulators, and physicians play in bridging the gap between clinical trial results and full commercial drug availability. View session here View session here
Biopharma strategy: More focus, more value? Biopharma strategy: More focus, more value?November 3, 2014 | BIO-Europe® 2014Pharma executives discuss their strategies for remaining opportunistic in an era of focused R&D. Is high risk, high reward the best strategy for funding unmet medical needs? View session here View session here
Translational medicine: Transforming research achievements into innovative therapeutic and diagnostic products Translational medicine: Transforming research achievements into innovative therapeutic and diagnostic productsNovember 3, 2014 | BIO-Europe® 2014The translation of biomedical research into effective therapeutics and diagnostics is the driving factor for innovation. Successful translation depends on the right strategy. View session here View session here
Interview with Rainer Strohmenger Interview with Rainer StrohmengerNovember 5, 2013 | BIO-Europe® 2013Rainer Strohmenger, Wellington Partners, discusses his firm's investment criteria and outlook for the medtech industry. View session here View session here
Interview with Regina Hodits Interview with Regina HoditsNovember 5, 2013 | BIO-Europe® 2013Regina Hodits of Wellington Partners discusses her approach to medtech investing and how she is finding novel technologies in the US to be funded in Europe. View session here View session here
Interview with Timothy Herpin Interview with Timothy HerpinNovember 5, 2013 | BIO-Europe® 2013Timothy Herpin discusses AstraZeneca's new partnering strategy focused around three core therapeutic areas, and how the BD organization is set up to keep the deals and company moving. View session here View session here
A  day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2013 A day in the life of experienced dealmakers: Transformational deals that shaped the industry in 2013November 5, 2013 | BIO-Europe® 2013Transformative deals from 2013 were discussed among pharmaceutical company leaders, who spoke on aligning their corporate strategies to restore growth, and collaboration criteria. View session here View session here
What is the role of large pharma in developing advanced therapy medicinal products—are they essential or not? What is the role of large pharma in developing advanced therapy medicinal products—are they essential or not?November 4, 2013 | BIO-Europe® 2013This panel discusses the opportunities for regenerative medicine and advanced therapies in the larger disease populations where expenses will be greater and timelines longer. View session here View session here
The right deal at the right time: How are sell-side dealmakers getting it right, or wrong, in today's environment? The right deal at the right time: How are sell-side dealmakers getting it right, or wrong, in today's environment?November 4, 2013 | BIO-Europe® 2013Several executives from clinical-stage biotech companies give a firsthand account of their strategies, challenges faced and outcomes of the partnering experience. View session here View session here
Major deal transactions Major deal transactionsNovember 4, 2013 | BIO-Europe® 2013Panelists examine significant deals of the last 12 months, and what these deals reveal about pharma's priorities, strategy and options when seeking a corporate partner. View session here View session here
How to position your asset for the optimal deal How to position your asset for the optimal dealNovember 4, 2013 | BIO-Europe® 2013In an overview of key success factors for enhancing your dealmaking success with pharma, both pharma and leading consulting firms come together to help you prepare for the deal. View session here View session here
Building the drug pipeline of tomorrow: Capturing the potential of the academic research enterprise Building the drug pipeline of tomorrow: Capturing the potential of the academic research enterpriseNovember 4, 2013 | BIO-Europe® 2013In order to preserve a robust drug pipeline it is essential to nurture the potential for academic research. How can the obstacles between industry and academics be overcome? View session here View session here
The Onyx story: Creating a leading oncology company The Onyx story: Creating a leading oncology companyNovember 4, 2013 | BIO-Europe® 2013Tony Coles speaks on the success of the Onyx competitive R&D strategy as the lead up to their recent acquisition by Amgen. View session here View session here
Is nano becoming the next sweet spot for drug development? Is nano becoming the next sweet spot for drug development?November 4, 2013 | BIO-Europe® 2013After starting out as drug-delivery systems, nanomaterials are now being used as the active principle for treating diseases, with nano-therapeutics commencing clinical development. View session here View session here
Public funding in drug development: Analyzing the dose-effect relationship Public funding in drug development: Analyzing the dose-effect relationshipNovember 4, 2013 | BIO-Europe® 2013Government funding has become an important source of finance in the biotech industry. But what role should government play? Can they be as nimble as traditional venture players? View session here View session here
How can R&D strategy influence patient outcomes? How can R&D strategy influence patient outcomes?November 4, 2013 | BIO-Europe® 2013Pharmaceutical executives share their perspectives on their evolving R&D strategies and the increasing influence of patient groups as advocates. View session here View session here
Interview with Christian Rohlff, Oxford BioTherapeutics Interview with Christian Rohlff, Oxford BioTherapeuticsNovember 13, 2012 | BIO-Europe® 2012Christian Rohlff of Oxford BioTherapeutics discusses his company's unique targeted antibody-based platform for developing new drugs and companion diagnostics. View session here View session here
Interview with Richard Soll, WuXi AppTec Interview with Richard Soll, WuXi AppTecNovember 13, 2012 | BIO-Europe® 2012Since its founding in 2000, WuXi AppTec has grown to become one the industry's leading CROs. Richard Soll discusses WuXi's approach to working with both big pharma and smaller biotech. View session here View session here
Interview with Stephen Evans-Freke, Celtic Therapeutics Interview with Stephen Evans-Freke, Celtic TherapeuticsNovember 13, 2012 | BIO-Europe® 2012Successful entrepreneur Stephen Evans-Freke shares his views on investment strategy in the current financial climate. View session here View session here
Reinvigorating pharma pipelines through companion diagnostics

Reinvigorating pharma pipelines through companion diagnostics November 12, 2012 | BIO-Europe® 2012Companion Dx and targeted therapies have revolutionized patient treatment, but uncertainty has plagued relationships between drug companies and diagnostic developers. View session here View session here
Pricing a new product: Are comparative effectiveness systems setting the floor or the ceiling? Pricing a new product: Are comparative effectiveness systems setting the floor or the ceiling?November 12, 2012 | BIO-Europe® 2012Are comparative effectiveness systems making health systems more efficient and effective in delivering the best treatments, or are they impeding market access for promising new medicines? View session here View session here
Forging new partnerships for drug development Forging new partnerships for drug developmentNovember 12, 2012 | BIO-Europe® 2012This panel examines the relationships between top CROs and their changing and evolving customer base, and the extent to which the global reach of these firms can be leveraged effectively. View session here View session here
Early stage collaborations: What's your role in the pre-competitive space? Early stage collaborations: What's your role in the pre-competitive space?November 12, 2012 | BIO-Europe® 2012This panel examines the different corporate perspectives on open innovation and how pre-competitive deals are structured to meet each company's ultimate need to compete downstream. View session here View session here
New pharma strategies: Refining the R&D blueprint New pharma strategies: Refining the R&D blueprintNovember 12, 2012 | BIO-Europe® 2012Increasing pressure to heighten productivity and lower cost has led many pharma companies to completely rethink their R&D and commercialization strategies. View session here View session here
Crucial decisions around asset valuation and deal terms Crucial decisions around asset valuation and deal termsNovember 12, 2012 | BIO-Europe® 2012Make the best long range decisions when developing an asset by focusing on specific vs. multiple indications, the future market, appropriate partners, and a good clinical development plan. View session here View session here
Personalized oncology and next gen cancer drug development Personalized oncology and next gen cancer drug developmentNovember 12, 2012 | BIO-Europe® 2012This session explores how new technologies and novel therapeutic approaches impact advances in cancer drug development and help us deliver on the promise of personalized medicine. View session here View session here
New investment models for early stage development New investment models for early stage development November 12, 2012 | BIO-Europe® 2012New funding initiatives for early stage production include strategic pharma relationships focusing on the end consumer and increasing diversification. View session here View session here



About the BIO-Europe® Conference

BIO-Europe® 2013 Highlights

  • 3,202 attendees
  • 17,874 one-to-one meetings
  • 3,599 licensing opportunities posted
  • 1,841 companies
  • 184 company presentations
  • 95 exhibitors
  • 56 countries represented
  • 18 workshops and panels
  • 11 Academic Innovators™ presentations

Photos of BIO-Europe 2013 ►

Building value through partnerships

BIO-Europe® is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. Produced with the support of BIO, it is regarded as a “must attend” event for the biotech industry.

Featuring EBD Group's sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups. more ►




Who will you meet?

BIO-Europe plays host to executives from:

  • Established and emerging biotech companies
  • Pharmaceutical companies
  • Academic innovators
  • Private investors including venture capital and private equity
  • Companies developing companion diagnostics
  • Other industry related service companies

Breakdown of registrants and participating companies at BIO-Europe

Previous Conferences ►

BIO-Europe features

One-to-one partnering meetings
One-to-one partnering meetings
partneringONE® enables participants to identify and select potential partners. The system—industry-specific, web-based and interactive—is uniquely suited for the needs of life science companies. more

Sessions
Sessions
Panels and workshops feature corporate leaders who share insight, opinion and advice on how to navigate industry challenges. more

Company presentations
Company presentations
Select biotechnology, midsize and big pharmaceutical companies present their products and technologies and corporate strategies in 14-minute presentations. more

Exhibition
Exhibition
A lively exhibition in the heart of the conference area showcases companies, services and technologies. more

Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe EBD Group BIO BIO-Europe